Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

GPhA’s Neas Preaches Vigilance Against Reopening Hatch-Waxman Act

20 Feb 2012

• By Sue Sutter

Related Content

FDA’s Drug Shortage Reg Adds More Manufacturers, Products To Notification List

19 Dec 2011

FDA Biosimilars Guidances Address Immunogenicity Studies, European Bridge Data, Analytics

13 Feb 2012

GPhA After Jaeger: Will Industry Pressures Push Firms Together Or Pull Association Apart? New CEO Must Face Down FOBs

10 May 2010

Exclusivity For Biologics, Drugs Should Be The Same After All, Grabowski Says

07 Nov 2011

GPhA's New CEO Ralph Neas Brings Health Reform Advocacy Experience

12 Sep 2011

Related Companies

Fresenius SE & Co. KGaA

Teva Pharmaceutical Industries Ltd.

Novartis AG

Hospira, Inc.

Additional Topics

Legislation Post Market Regulation & Studies BioPharmaceutical

More from Legislation

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.